November 14, 2019 09:37 AM EST

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

Amber Tong

After AbbVie became a formidable player in medical aesthetics overnight by swallowing Allergan, the Botox maker is beefing up the pipeline with new R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

Amber Tong

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Al­ler­gan en­lists Ex­i­cure in search of hair loss drugs with $25M up­front, dou­bling down on area dear to Ab­b­Vie

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie